4DMedical Limited (ASX:4DX)
Australia
· Delayed Price · Currency is AUD | Market Cap | 2.78B |
| Revenue (ttm) | 5.81M |
| Net Income (ttm) | -172.93M |
| Shares Out | 590.57M |
| EPS (ttm) | -0.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,728,892 |
| Average Volume | 6,907,322 |
| Open | 4.990 |
| Previous Close | 4.970 |
| Day's Range | 4.680 - 4.990 |
| 52-Week Range | 0.230 - 7.550 |
| Beta | 2.21 |
| RSI | 40.81 |
| Earnings Date | May 27, 2026 |
About 4DMedical
4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in the medical research technology and development of a non‑invasive respiratory imaging solution using four‑dimensional imaging. It offers CT:VQ, non contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of poten... [Read more]
Financial Performance
In fiscal year 2025, 4DMedical's revenue was 5.85 million, an increase of 55.91% compared to the previous year's 3.75 million. Losses were -30.07 million, -16.42% less than in 2024.
Financial StatementsNews
4DMedical Transcript: AI & Technology Virtual Investor Conference
A software-driven imaging platform is rapidly displacing nuclear VQ scans in the U.S. with a CT-based alternative, offering faster, safer, and more accessible diagnostics. Strategic partnerships and rapid adoption at top hospitals are fueling expansion, with plans to grow the addressable market and enter new regions.
4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union
In a separate announcement made today, the Company also secured A$83 million in private placement funding to support growth initiatives, including European expansion. MELBOURNE, Australia, March 30, 2...
4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging
Funding will scale hospital deployments for groundbreaking CT:VQ™ imaging product, strongly advance R&D, support early adopters at Stanford, Cleveland Clinic, University of Miami, UC San Diego Health,...
4DMedical Transcript: Investor Update
CT:VQ, a non-invasive lung imaging software, is gaining strong traction with leading U.S. hospitals and benefits from a major partnership with Philips, including a minimum order commitment and government exclusivity. The company is well-funded, has robust IP protection, and is focused on rapid market expansion and reference customer acquisition.
4DMedical's CT:VQ™ receives FDA 510(k) clearance; First-and-only CT-based VQ technology
Medicare confirms reimbursement, unlocking nationwide access to non-contrast ventilation–perfusion imaging from routine chest CT LOS ANGELES , Sept. 4, 2025 /PRNewswire/ -- 4DMedical, a leader in adva...
4DMedical Transcript: Investor Update
FDA approval for CTV-Q enables immediate U.S. rollout, targeting a $1.1 billion market with instant scalability via existing CT infrastructure. Clinical validation shows strong equivalence to nuclear VQ, with superior workflow, economics, and patient experience. Commercialization leverages direct and partner channels, with reimbursement expected this year.
4DMedical Transcript: Status Update
CTVQ is positioned to disrupt the nuclear VQ imaging market by offering a faster, more accessible, and cost-effective solution using existing CT infrastructure. Clinical validation shows strong equivalence and some superiority to SPECT, with robust support from clinicians and expanding partnerships driving rapid adoption.
4DMedical Earnings Call Transcript: H1 2025
Revenue grew 16.5% half-on-half, with scan volume up 37% and operating expenditure down 11%. FDA and Medicare wins, a $12.5M capital raise, and the Philips partnership position the company for strong U.S. growth and a path to break-even.
4DMedical Transcript: Investor Update
Lung diagnostics is a multi-billion-dollar market hampered by outdated technologies, but new software-driven CT solutions are driving rapid revenue and site growth. Strategic partnerships, especially with Philips, and new products like CT VQ position the company for major market disruption and expansion.